In 2022, BioMarin Pharmaceutical completed a corporate carbon footprint assessment and publicly disclosed its greenhouse gas (GHG) emissions according to the GHG Protocol, covering Scope 1 (direct emissions from owned or controlled sources) and Scope 2 (indirect emissions from purchased energy).
However, BioMarin Pharmaceutical has not published a category-level breakdown of its Scope 3 emissions, limiting visibility into specific value chain sources.
| Metric (tCO2e) | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|
Total Scope 1 | 14,000a | 15,000a | 15,000a | |
Total Scope 2 | ||||
Location-Based | 9,000a | 8,000a | 7,000a | |
Total Scope 3 | N/A | N/A | N/A | |
Total Scope 1 Revenue Intensity (tCO2e/$M) | 6.6793a | 8.1245a | 8.0625a |
You are welcome to quote or reference individual data points from this page, provided you include the following attribution with a visible, clickable link to this page: "Source: Tracenable, the global reference for ESG data"
Bulk collection, scraping, resale, or redistribution of data across multiple company profiles is not permitted without our prior written permission. For more information, see our General Terms and Conditions.
Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform.
In 2022, the total operational greenhouse gas (GHG) emissions of BioMarin Pharmaceutical amounted to 23,000 metric tons of CO2 equivalent. This figure includes both direct emissions from owned or controlled sources (Scope 1) and indirect emissions from purchased energy (Scope 2).a
0In 2022, the total Scope 1 emissions of BioMarin Pharmaceutical were 14,000 metric tons of CO₂ equivalent (tCO₂e).a
Since 2020, BioMarin Pharmaceutical's Scope 1 emissions have decreased by 6.67%, reflecting a declining long-term trend in Scope 1 emissions over time.a
Compared to the previous year (2021), BioMarin Pharmaceutical's Scope 1 emissions decreased by 6.67%, highlighting the company's efforts to lower direct emissions from assets it owns or controls.a
In 2022, BioMarin Pharmaceutical reported Scope 2 greenhouse gas (GHG) emissions of 9,000 tCO₂e using the location-based method.a
Since 2020, BioMarin Pharmaceutical's Scope 2 greenhouse gas (GHG) emissions (Location-Based) have increased by 28.57%, reflecting a rising long-term trend in Scope 2 emissions over time.a
Compared to the previous year (2021), BioMarin Pharmaceutical's Scope 2 emissions (Location-Based) rose by 12.5% in 2022, suggesting that the company faced challenges in reducing emissions from purchased electricity and energya
In 2022, BioMarin Pharmaceutical reported its Scope 2 emissions using the location-based method.a
In 2022, BioMarin Pharmaceutical reported Scope 1 greenhouse gas (GHG) emissions of 14,000 tCO₂e and total revenues of USD 2,096 millions. This translates into an emissions intensity of 6.68 tCO₂e per millions USD.a
In 2022, BioMarin Pharmaceutical reported a Scope 1 emissions intensity of 6.68 tCO₂e per millions USD. Compared to the peer group median of 4.12, this places the company above its industry benchmark, indicating it is less carbon-efficient than most competitors.a
In 2022, BioMarin Pharmaceutical ranked 14 out of 21 companies in its industry peer group, based on Scope 1 emissions intensity (measured in tCO₂e per millions USD).a
BioMarin Pharmaceutical is therefore positioned in the mid-range of its industry, neither a clear leader nor a laggard in carbon efficiency.a